Emergency Medicine · Indianapolis, IN
NPI
1578727327
Since 2008
Specialty
Emergency Medicine
Code 207P00000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1701 N Senate Blvd., Room Ag001
Indianapolis, IN, 46202
Phone (317) 962-3886
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,709
91 services
Medicare patients, 2024
88
Average age 68
Drug cost, 2024
$32.0M
146,403 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lindsay M Weaver was code 99285 (emergency department e&m), 52 times for 51 patients. In total Lindsay M Weaver billed 91 services in 6 codes, and Medicare paid $9,709.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-02-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99285 Emergency Department E&M | Facility | 52 | 51 | $127.91 | $6,652 |
| 99284 Emergency Department E&M | Facility | 26 | 26 | $88.43 | $2,299 |
By year: 2022 $9,144 for 66 services; 2023 $9,316 for 89 services; 2024 $9,709 for 91 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lindsay M Weaver prescribed most often to Medicare patients was Arexvy (Rsvpref3 Antigen/As01e/Pf), with 51,834 prescriptions and refills. In total Lindsay M Weaver wrote 146,403 Medicare prescriptions that cost $32.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Arexvy Rsvpref3 Antigen/As01e/Pf | 51,834 | 51,834 | 51,659 | $13.8M |
| Shingrix Varicella-Zoster Ge/As01b/Pf | 39,949 | 39,955 | 29,586 | $7.6M |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | 31,307 | 31,318 | 31,211 | $8.7M |
| Boostrix Tdap Diphth,pertuss(Acell),tet Vac | 12,921 | 12,928 | 12,868 | $760K |
| Twinrix Hepatitis A And B Vaccine/Pf | 6,314 | 6,314 | 4,039 | $774K |
| Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf | 1,506 | 1,508 | 1,504 | $90K |
| Naloxone Hcl Generic | 1,251 | 1,257 | 1,155 | $72K |
| Havrix Hepatitis A Virus Vaccine/Pf | 566 | 566 | 531 | $51K |
| M-M-R Ii Vaccine Measles,mumps,rubella Vacc/Pf | 251 | 251 | 238 | $25K |
| Mresvia Rsv Vaccine, Pref, Mrna/Pf | 139 | 139 | 139 | $43K |
| Gardasil 9 Hpv Vaccine 9-Valent/Pf | 75 | 75 | 55 | $22K |
| Vaqta Hepatitis A Virus Vaccine/Pf | 59 | 59 | 55 | $5,391 |
| Tenivac Tetanus-Diphtheria Toxoids/Pf | 38 | 38 | 38 | $1,851 |
| Menquadfi Mening Vac A,c,y,w135,c-Tet/Pf | 33 | 33 | 32 | $5,548 |
| Heplisav-B Hepatitis B Vaccine/Cpg1018/Pf | 30 | 30 | 22 | $4,610 |
Brand drugs: 145,108 claims; generic drugs: - claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Lindsay M Weaver were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.